An interventional study of Sulforaphane in Autism, Autism Spectrum Disorder and Autistic Disorder, sponsored by Rutgers, The State University of New Jersey. Enrolling by invitation at 1 site in United States. Open to male participants aged 13 Years to 30 Years. Per ClinicalTrials.gov, last updated 2025-10-30.
Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 604 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.
Among the 604 studies in Autistic Disorder with a site in United States, this one is the 444th largest by planned enrollment of the 505 interventional ones that give a count, is one of 27 that started in 2022, is one of 296 with no phase, reaches primary completion later than 47 of the 150 other live ones, and was the 394th registered.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
Browse Autistic Disorder studies →123 of the 604 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 8–12
Northeastern University · Sites in United States
Ages 33 mo–71 mo
Vanderbilt University Medical Center · Sites in United States
Ages 36 mo–72 mo
University of Wisconsin, Madison · Sites in United States
Massachusetts General Hospital · Sites in United States
Ages 7–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.
This study: 13 Years to 30 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
604 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 122 · Phase 3 43 · Phase 4 18
First in 1997; this study’s year is marked. 27 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Median enrollment 44 across the 505 interventional studies, 135 across the 96 observational. Of the 409 that completed or were terminated, 143 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 604 have an industry lead sponsor. The 10 most frequent:
Rutgers, The State University of New Jersey is the lead sponsor of 507 studies on the registry; 132 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.
Rutgers, The State University of New Jersey has 6 studies filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
34 of the studies in Autistic Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02914951Yale UniversityCognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability | 2026-12 |
| NCT06627205Stanford UniversitySleep Restriction Therapy (SRT) for Sleep Problems in Children With Autism | 2026-12 |
| NCT04805957Rutgers, The State University of New JerseyValidation Digital Bio-markers During Sulforaphane Treatment. | 2026-12-01 |
| NCT07421830Northeastern UniversityAn Empowering Parent Training Intervention to Increase Physical Activity in Preschool Aged Children With Autism | 2026-12-31 |
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
Add all 34 to your calendar (.ics) → With an account.
Among the 604 studies in Autistic Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the research is to determine if changes seen during sulforaphane treatment (a compound that comes from eating certain vegetables) can better be understood using digital biomarkers. These digital biomarkers are things like heart rate, muscle movement etc. and are measured using non-invasive devices (like a watch) and are aimed at complementing the traditional clinical scores already in use in current trials (e.g. Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS) and Ohio Autism Clinical Impressions Scale (OACIS)).
This study is a pilot open label treatment trial with SF (sulforaphane) in 10 individuals that have completed with moderate to severe autism, age 13-30 years that have completed participation in ClinicalTrials.gov Identifier: NCT02677051. This study will measure digital biomarkers of the nervous systems. Digital biomarkers are obtained by using non-invasive wireless (wearable, like wearing a watch) biosensors that co-register in tandem multiple biorhythms self-generated by the person's nervous systems. These sensors gather a very large amount of data from measures such as EEG (electroencephalogram), EKG (electrocardiogram), kinematics and others. These measures are done at the same time as the clinical evaluations and so results can be compared. Because the data are based on the unique fingerprint-like signatures of the person's nervous systems, it is possible to ascertain the person's progression in response to treatment and compare it to baseline states. The project will also compare these self-emerging clusters between subjects, possibly identifying patterns that correlate with sub-phenotypes or with similarities in response to treatment. Changes in things such as natural behaviors, an individual's ability or desire to interact socially and ability or desire to communicate will alter the signature profiles from baseline. Since these changes are dynamic in nature, trends of the evolving patterns and separate changes that are a consequence of the treatment vs. changes that are part of the natural neurodevelopment can be detected. This may be a valuable tool in future studies of underlying etiology. The technology used to perform these measures and the software to analyze the data are evolving rapidly. Last, with the characterized signatures and possibly overlapping patterns generated in this and in other projects it is foreseeable that a clinically relevant tool for measures in autism will follow.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive 1.47umol/kg/day sulforaphane for 12 weeks. Pills are taken once a say with a meal.
Dietary Supplement: Sulforaphane
Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.
Also known as: Avmacol®
Aberrant Behavior Checklist (ABC)
Rating scale to measure severity aberrant behaviors
Time frame: Baseline.
Aberrant Behavior Checklist (ABC)
Rating scale to measure severity aberrant behaviors
Time frame: Week 6.
Aberrant Behavior Checklist (ABC)
Rating scale to measure severity aberrant behaviors
Time frame: Week 12, end of treatment.
Aberrant Behavior Checklist (ABC)
Rating scale to measure severity aberrant behaviors
Time frame: Week 16.
Social Responsiveness Scale (SRS)
Rating scale to measure social interaction.
Time frame: Baseline.
Social Responsiveness Scale (SRS)
Rating scale to measure social interaction.
Time frame: Week 6.
Social Responsiveness Scale (SRS)
Rating scale to measure social interaction.
Time frame: Week 12, end of treatment.
Social Responsiveness Scale (SRS)
Rating scale to measure social interaction.
Time frame: Week 16.
Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)
Rating scale to measure autism severity and changes in severity.
Time frame: Baseline.
Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)
Rating scale to measure autism severity and changes in severity.
Time frame: Week 6.
Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)
Rating scale to measure autism severity and changes in severity.
Time frame: Week 12, end of treatment.
Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)
Rating scale to measure autism severity and changes in severity.
Time frame: Week 16.
Digital Biomarkers
Non-invasive biosensor measurements of micro-movements.
Time frame: Baseline.
Digital Biomarkers
Non-invasive biosensor measurements of micro-movements.
Time frame: Week 6.
Digital Biomarkers
Non-invasive biosensor measurements of micro-movements.
Time frame: Week 12, end of treatment.
Digital Biomarkers
Non-invasive biosensor measurements of micro-movements.
Time frame: Week 16.
EEG
Electroencephalogram (EEG) measures electrical activity of the brain.
Time frame: Baseline
EEG
Electroencephalogram (EEG) measures electrical activity of the brain.
Time frame: Week 6.
EEG
Electroencephalogram (EEG) measures electrical activity of the brain.
Time frame: Week 12, end of treatment.
EEG
Electroencephalogram (EEG) measures electrical activity of the brain.
Time frame: Week 16.
EKG
Electrocardiogram (ECG or EKG) measures electrical signals from the heart.
Time frame: Baseline
EKG
Electrocardiogram (ECG or EKG) measures electrical signals from the heart.
Time frame: Week 6.
EKG
Electrocardiogram (ECG or EKG) measures electrical signals from the heart.
Time frame: Week 12, end of treatment.
EKG
Electrocardiogram (ECG or EKG) measures electrical signals from the heart.
Time frame: Week 16.
Electrophysiological recordings.
Measurement of electrical activity in Tissue.
Time frame: Baseline
Electrophysiological recordings.
Measurement of electrical activity in Tissue.
Time frame: Week 6.
Electrophysiological recordings.
Measurement of electrical activity in Tissue.
Time frame: Week 12, end of treatment.
Electrophysiological recordings.
Measurement of electrical activity in Tissue.
Time frame: Week 16.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.
Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 52 months is above that.
Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sulforaphane
Rutgers, The State University of New Jersey →